Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 16:15:122.
doi: 10.1186/s12894-015-0116-4.

Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry

Götz Geiges  1 , Thomas Harms  2 , Gerald Rodemer  3 , Ralf Eckert  4 , Frank König  5 , Rolf Eichenauer  6 , Jörg Schroder  7
Affiliations

Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry

Götz Geiges et al. BMC Urol. .

Abstract

Background: We investigated the use of the gonadotropin-releasing hormone (GnRH) antagonist degarelix in everyday clinical practice using registry data from uro-oncology practices in Germany.

Methods: Data were analysed retrospectively from the IQUO (Association for uro-oncological quality assurance) patient registry. Data were prospectively collected from all consecutive PCa patients treated with degarelix (n = 1010) in 138 uro-oncology practices in Germany between May 2009 and December 2013.

Results: Median overall survival had not yet been reached in the all-patient group or in subgroups who had or had not received prior hormonal therapy (HT). Cox regression analysis showed that patients who had received prior HT (n = 542) had a 58 % increased mortality risk (hazard ratio 1.58, 95 % CI 1.20-2.09) versus patients who had not (n = 468) (p = 0.001). Also, in patients who had received prior luteinizing hormone-releasing hormone (LHRH) analogue therapy (LHRH agonists or GnRH antagonists), median time to PSA progression was shorter (209 weeks) than in those who had not received prior LHRH analogues (n = 555; median PSA progression-free survival not yet reached). Degarelix was generally well tolerated.

Conclusions: Degarelix was effective and well tolerated in everyday clinical practice, confirming observations from clinical studies. Patients who received prior HT appeared to have a significantly higher mortality risk.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient response to treatment over time
Fig. 2
Fig. 2
Percentage change in median PSA over time in (a) all patients; b patients with metastatic disease at baseline; c patients with prior hormonal therapy; and (d) patients with no prior hormonal therapy
Fig. 3
Fig. 3
Percentage of patients with PSA ≤ 4 ng/ml over time for (a) all patients; b patients with metastatic disease at baseline; and (c) patients with baseline PSA ≥20 ng/ml
Fig. 4
Fig. 4
Percentage change in median serum alkaline phosphatase over time in (a) patients with metastatic disease at baseline and (b) patients with no prior hormonal therapy
See this image and copyright information in PMC

References

    1. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–1538. doi: 10.1111/j.1464-410X.2008.08183.x. - DOI - PubMed
    1. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011;186(3):889–897. doi: 10.1016/j.juro.2011.04.083. - DOI - PubMed
    1. Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, et al. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn J Clin Oncol. 2012;42(6):477–484. doi: 10.1093/jjco/hys035. - DOI - PubMed
    1. Van Poppel H. LHRH agonists versus GnRH antagonists for the treatment of prostate cancer. Belgian J Med Oncol. 2010;4:18–22.
    1. Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol. 2001;3(Suppl 3):S10–14. - PMC - PubMed

Publication types

MeSH terms

Substances